Sanction triggers $23 million milestone fee to Genmab.

Genmab received an approximately $23 million milestone payment from GlaxoSmithKline through the company’s achievement of accelerated FDA approval of the CD20-targeting mAb Arzerra™ (ofatumumab) as a treatment for chronic lymphocytic leukemia (CLL).

Approval covers the use of Arzerra in patients with CLL that is refractory to fludarabine and alemtuzumab.  A regulatory filing in the EU for the CLL indication was made in February.

The antibody is also in Phase III development against non-Hodgkin’s lymphoma and rheumatoid arthritis. Additionally, Phase II trials are under way in multiple sclerosis and diffuse large B-cell lymphoma. “This approval marks a key milestone for Genmab as it is our first antibody to reach the market,” notes Lisa N Drakeman, Ph.D., CEO.

GSK and Genmab signed their worldwide agreement to co-develop and commercialize ofatumumab for multiple indications in December 2006. Under terms of the original agreement Genmab received a license fee of some $102 million. GSK also made a $357 million investment in the Danish company. The firms estimated the total value of the deal could reach about $2.1 billion, including future milestones in the various indications. 

In December 2008, Genmab decided to sell back its U.S. and Nordic region co-promotion rights to GSK for a one-time fee of $4.5 million. This was due upon the successful filing of ofatumumab in the U.S. for an oncology indication. The amendment means GSK is now fully responsible for sales of the antibody worldwide.

Previous articleScripps-Led Consortium that Combines Physics and Oncology Receives $10M
Next articlePPD to Spin Out Compound-Partnering Segment, Acquire Chinese CRO, and Invest $100M in Celtic Therapeutics